Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
6 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
German Tech Holding (GTH) is exploring an investment in Zirnostics GmbH, a biotech startup developing a zirconium-89-labelled tracer for prostate cancer diagnostics. The technology offers significantly higher tumour-to-background contrast, potentially improving detection of tumour foci and metastases.
German Tech Holding (GTH) is considering a 10% investment in Zirnostics GmbH, a biotech startup developing a zirconium-89-labeled radiopharmaceutical for improved prostate cancer diagnostics. The technology shows potential for early detection of tumor foci and metastases.
German Tech Holding GmbH & Co. KGaA is considering an investment in a biotechnology startup that has developed a disruptive radiopharmaceutical for cancer diagnostics, which has shown clinical proof.
German Tech Holding GmbH & Co. KGaA is examining an investment of 10% in Zirnostics GmbH, a biotech startup developing a zirconium-89-based radiopharmaceutical for prostate cancer diagnostics.
German Tech Holding GmbH & Co. KGaA is examining a potential investment in a BioTech startup that has developed a disruptive radiopharmaceutical for cancer diagnostics.
German Tech Holding GmbH & Co. KGaA (GTH) is examining a potential investment in a BioTech startup that has developed a disruptive radiopharmaceutical for cancer diagnostics.